Literature DB >> 21987725

Targeting PI3K/mTOR signaling in cancer.

Brooke M Emerling1, Argun Akcakanat.   

Abstract

The American Association for Cancer Research (AACR) Special Conference on Targeting PI3K/mTOR Signaling in Cancer was held in San Francisco, California from February 24 to 27, 2011. The meeting was cochaired by Drs. Lewis C. Cantley, David M. Sabatini, and Funda Meric-Bernstam. The main focus of this event was the therapeutic potential of drugs targeting the PI3K/mTOR signaling pathway for the treatment of cancer. This article summarizes the recent discoveries in the field, with particular emphasis on the major themes of the conference.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21987725     DOI： 10.1158/0008-5472.CAN-11-1699

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  17 in total

1.  Elovl5 regulates the mTORC2-Akt-FOXO1 pathway by controlling hepatic cis-vaccenic acid synthesis in diet-induced obese mice.

Authors:  Sasmita Tripathy; Donald B Jump
Journal:  J Lipid Res       Date:  2012-10-24       Impact factor: 5.922

2.  Combination Therapy: JAK PI3K/mTOR. A Novel Approach for Cancer Treatment.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2013-03-22       Impact factor: 4.345

3.  MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.

Authors:  Yanyan Gu; Jonathan L Kaufman; Leon Bernal; Claire Torre; Shannon M Matulis; R Donald Harvey; Jing Chen; Shi-Yong Sun; Lawrence H Boise; Sagar Lonial
Journal:  Blood       Date:  2014-04-08       Impact factor: 22.113

4.  Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel.

Authors:  Yan Zhou; Jiyuan Yang; Rui Zhang; Jindřich Kopeček
Journal:  Eur J Pharm Biopharm       Date:  2014-12-03       Impact factor: 5.571

Review 5.  The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.

Authors:  Thomas R Webb; Amanda S Joyner; Philip M Potter
Journal:  Drug Discov Today       Date:  2012-08-03       Impact factor: 7.851

6.  PDK1 promotes tumor growth and metastasis in a spontaneous breast cancer model.

Authors:  J Du; M Yang; S Chen; D Li; Z Chang; Z Dong
Journal:  Oncogene       Date:  2015-10-12       Impact factor: 9.867

7.  PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.

Authors:  Amanda Herzog; Yansong Bian; Robert Vander Broek; Bradford Hall; Jamie Coupar; Hui Cheng; Anastasia L Sowers; John D Cook; James B Mitchell; Zhong Chen; Ashok B Kulkarni; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2013-05-02       Impact factor: 12.531

Review 8.  Recent discoveries in the cycling, growing and aging of the p53 field.

Authors:  James A McCubrey; Zoya N Demidenko
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

Review 9.  Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

Authors:  Alberto M Martelli; Francesca Chiarini; Camilla Evangelisti; Alessandra Cappellini; Francesca Buontempo; Daniela Bressanin; Milena Fini; James A McCubrey
Journal:  Oncotarget       Date:  2012-04

10.  Inhibition of mammalian target of rapamycin by rapamycin increases the radiosensitivity of esophageal carcinoma Eca109 cells.

Authors:  Dejun Zhang; Jie Xiang; Yuming Gu; Wei Xu; Hao Xu; Maoheng Zu; Dongsheng Pei; Junnian Zheng
Journal:  Oncol Lett       Date:  2014-05-27       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.